Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 31:3:4.
doi: 10.3389/fphar.2012.00004. eCollection 2012.

Sirtuins and disease: the road ahead

Vincenzo Carafa  1 , Angela Nebbioso, Lucia Altucci
Affiliations

Sirtuins and disease: the road ahead

Vincenzo Carafa et al. Front Pharmacol. .

Abstract

Sirtuins represent a promising new class of conserved histone deacetylases, originally identified in yeast. The activity of the sirtuin (SirT) family - made up of seven members (SirT1-7) - is NAD(+) dependent. Sirtuins target a wide range of cellular proteins in nucleus, cytoplasm, and mitochondria for post-translational modification by acetylation (SirT1, 2, 3, and 5) or ADP-ribosylation (SirT4 and 6). Sirtuins regulate responses to stress and ensure that damaged DNA is not propagated, thus contrasting the accumulation of mutations. To date, sirtuins have emerged as potential therapeutic targets for treatment of human pathologies such as metabolic, cardiovascular and neurodegenerative diseases, and cancer. SirT1 is the founding member of this class of enzymes and is currently the best known of the group. SirT1 acts in various cellular processes, deacetylating both chromatin and non-histone proteins, and its role in cancer and aging has been extensively studied. SirT1 may play a critical role in tumor initiation and progression as well as drug resistance by blocking senescence and apoptosis, and by promoting cell growth and angiogenesis. Recently, growing interest in sirtuin modulation has led to the discovery and characterization of small molecules able to modify sirtuin activity. The present review highlights SirT mechanism(s) of action and deregulation in cancer, focusing on the therapeutic potential of SirT modulators both in cancer prevention and treatment.

Keywords: SirT inhibitors; cancer; epigenetics; human diseases; sirtuins.

PubMed Disclaimer

References

    1. Alcaín F. J., Villalba J. M. (2009). Sirtuin inhibitors. Expert Opin. Ther. Pat. 19, 283–29410.1517/13543770902762893 - DOI - PubMed
    1. Araki T., Sasaki Y., Milbrandt J. (2004). Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305, 1010–101310.1126/science.1098014 - DOI - PubMed
    1. Ashraf N., Zino S., Macintyre A., Kingsmore D., Payne A. P., George W. D., Shiels P. G. (2006). Altered sirtuin expression is associated with node-positive breast cancer. Br. J. Cancer 95, 1056–106110.1038/sj.bjc.6603384 - DOI - PMC - PubMed
    1. Bedalv A., Gatbonton T., Irvine W. P., Gottschling D. E., Simon J. A. (2001). Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. U.S.A. 15113–1511810.1073/pnas.261574398 - DOI - PMC - PubMed
    1. Borra M. T., Smith B. C., Denu J. M. (2005). Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187–1719510.1074/jbc.M501250200 - DOI - PubMed

LinkOut - more resources